Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting : vimarsana.com

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Major Histocompatibility Complex Class I negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers, due to the loss of the fundamental recognition of...

Related Keywords

California , United States , China , Boston , Massachusetts , San Diego Convention Center , San Diego , American , Thomas Schuetz , Danna Gifford , Senior Communications , American Association For Cancer Research , Compass Therapeutics Inc , Research Development At Compass , Presentations Of The Company , Exchange Commission , Elpiscience Biopharma Ltd , Handok Inc , Nasdaq , Globenewswire Inc , Cancer Research , Annual Meeting , Diego Convention Center , Checkpoint Inhibitor , Elpiscience Biopharma , Annual Report , Quarterly Report ,